ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
6 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
58
|
14K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
8 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
49
|
11K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
22 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
49
|
11K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
5 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
49
|
11K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
121 |
43K |
6 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
121
|
43K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
121 |
43K |
5 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
121
|
43K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
12 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
248
|
68K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
5 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
248
|
68K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
9 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
248
|
68K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
8 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
58
|
14K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
14 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
248
|
68K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
8 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
58
|
14K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
19 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
248
|
68K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
13 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
49
|
11K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
7 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
49
|
11K
|
7
|
|
ASX - By Stock
|
PAA |
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
2 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
49
|
11K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
12K |
14 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
61
|
12K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
12K |
11 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
61
|
12K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
20 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
248
|
68K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
12 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
248
|
68K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
39 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
248
|
68K
|
39
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
12 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
248
|
68K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
18 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
58
|
14K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
15 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
248
|
68K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
12K |
30 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
61
|
12K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
12K |
22 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
10 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
24 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
24
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
7 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
58
|
14K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
12 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
18 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
12K |
7 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
20 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
10 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
58
|
14K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
34 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
58
|
14K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
21 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
26 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
248
|
68K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
6 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
1 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
7 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
5 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
19 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
16 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
30 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
30
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
17 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
26 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
978
|
267K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
25 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
978
|
267K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
121 |
43K |
22 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
121
|
43K
|
22
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
22 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
978
|
267K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAAO HOLDERS AS AT 31/05/24
|
|
adreamer
|
24 |
7.0K |
12 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
24
|
7.0K
|
12
|
|